Quarterly ResultMay 6, 2026, 06:38 AM
Recursion Q1 Net Loss Narrows to $(117.5)M; Revenue $6.47M
AI Summary
Recursion Pharmaceuticals reported a reduced net loss of $(117.5) million for Q1 2026, an improvement from $(202.5) million in Q1 2025. Total revenue decreased to $6.47 million from $14.75 million year-over-year, while operating costs and expenses also saw a substantial reduction. The company also established a new at-the-market offering for up to $300 million of Class A common stock.
Key Highlights
- Q1 2026 net loss was $(117.5) million, down from $(202.5) million in Q1 2025.
- Total revenue for Q1 2026 decreased to $6.47 million from $14.75 million in Q1 2025.
- Net loss per share improved to $(0.22) in Q1 2026 from $(0.50) in Q1 2025.
- Research and development expenses fell to $87.9 million in Q1 2026 from $129.6 million in Q1 2025.
- General and administrative expenses decreased to $34.6 million in Q1 2026 from $54.7 million in Q1 2025.
- Net cash used in operating activities improved to $(81.1) million in Q1 2026 from $(132.0) million in Q1 2025.
- New at-the-market offering for up to $300 million of Class A common stock.
- Cash and cash equivalents were $654.5 million as of March 31, 2026.
Price Impact
More from RXRX